- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 565218, 14 pages
Hippocampal Gene Expression of Deiodinases 2 and 3 and Effects of 3,5-Diiodo-L-Thyronine T2 in Mouse Depression Paradigms
1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severnii proesd 1, Chernogolovka, Moscow Region 142432, Russia
2Timantti AB, Sundbyberg 104, 174 07 Stockholm, Sweden
3Department of Preventive Medicine, Maastricht Medical Center in Annadal, Becanusstraat 17 A0, 6216 BX Maastricht, Netherlands
4Carbone Cancer Center, University of Wisconsin, WIMR 3016, 1111 Highland Avenue, Madison, WI 53705, USA
5Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Baltiyskaia 8, Moscow 125315, Russia
6Department of Neuroscience, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 40, NL 6229 ER Maastricht, The Netherlands
7Institute for Hygiene and Tropical Medicine, New University of Lisbon, Rua da Junqueira 96, 1349-008 Lisbon, Portugal
Received 31 August 2013; Revised 3 November 2013; Accepted 3 November 2013
Academic Editor: Paul M. Tulkens
Copyright © 2013 Natalyia Markova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- G. Pinna, O. Brödel, T. Visser et al., “Concentrations of seven iodothyronine metabolites in brain regions and the liver of the adult rat,” Endocrinology, vol. 143, no. 5, pp. 1789–1800, 2002.
- G. Pinna, O. Broedel, M. Eravci et al., “Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation,” Biological Psychiatry, vol. 54, no. 10, pp. 1049–1059, 2003.
- A. Guadaño-Ferraz, M. J. Obregón, D. L. St Germain, and J. Bernal, “The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 19, pp. 10391–10396, 1997.
- M. J. Obregón, C. R. de Ona, R. Calvo, F. E. del Rey, and G. Morreale de Escobar, “Outer ring iodothyronine deiodinases and thyroid hormone economy: responses to iodine deficiency in the rat fetus and neonate,” Endocrinology, vol. 129, no. 5, pp. 2663–2673, 1991.
- F. Goglia, “Biological effects of 3,5-diiodothyronine (T2),” Biochemistry, vol. 70, no. 2, pp. 164–172, 2005.
- R. T. Joffe, “Is the thyroid still important in major depression?” Journal of Psychiatry and Neuroscience, vol. 31, no. 6, pp. 367–368, 2006.
- A. G. Trentin, “Thyroid hormone and astrocyte morphogenesis,” Journal of Endocrinology, vol. 189, no. 2, pp. 189–197, 2006.
- L. A. Desouza, U. Ladiwala, S. M. Daniel, S. Agashe, R. A. Vaidya, and V. A. Vaidya, “Thyroid hormone regulates hippocampal neurogenesis in the adult rat brain,” Molecular and Cellular Neuroscience, vol. 29, no. 3, pp. 414–426, 2005.
- T. Giordano, J. B. Pan, D. Casuto, S. Watanabe, and S. P. Arneric, “Thyroid hormone regulation of NGF, NT-3 and BDNF RNA in the adult rat brain,” Molecular Brain Research, vol. 16, no. 3-4, pp. 239–245, 1992.
- X. Moreau, R. Jeanningros, and P. Majjola-Pomietto, “Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT1A and 5-HT2A receptors in adult rat brain,” Neuropsychopharmacology, vol. 24, no. 6, pp. 652–662, 2001.
- V. A. Vaidya, M. E. Castro, Q. Pei, M. E. Sprakes, and D. G. Grahame-Smith, “Influence of thyroid hormone on 5-HT(1A) and 5-HT(2A) receptor-mediated regulation of hippocampal BDNF mRNA expression,” Neuropharmacology, vol. 40, no. 1, pp. 48–56, 2001.
- A. J. Cleare, A. McGregor, and V. O'Keane, “Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression,” Clinical Endocrinology, vol. 43, no. 6, pp. 713–719, 1995.
- G. Abraham, R. Milev, and J. Stuart Lawson, “T3 augmentation of SSRI resistant depression,” Journal of Affective Disorders, vol. 91, no. 2-3, pp. 211–215, 2006.
- M. Bauer, A. Heinz, and P. C. Whybrow, “Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain,” Molecular Psychiatry, vol. 7, no. 2, pp. 140–156, 2002.
- M. Eravci, G. Pinna, H. Meinhold, and A. Baumgartner, “Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain,” Endocrinology, vol. 141, no. 3, pp. 1027–1040, 2000.
- A. Antonelli, P. Fallahi, S. M. Ferrari et al., “3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects,” Journal of Biological Regulators and Homeostatic Agents, vol. 25, no. 4, pp. 655–660, 2011.
- P. de Lange, F. Cioffi, R. Senese et al., “Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats,” Diabetes, vol. 60, no. 11, pp. 2730–2739, 2011.
- M. Moreno, E. Silvestri, R. de Matteis et al., “3,5-diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations,” The FASEB Journal, vol. 25, no. 10, pp. 3312–3324, 2011.
- G. T. Rezin, G. Amboni, A. I. Zugno, J. Quevedo, and E. L. Streck, “Mitochondrial dysfunction and psychiatric disorders,” Neurochemical Research, vol. 34, no. 6, pp. 1021–1029, 2009.
- A. Lombardi, A. Lanni, M. Moreno, M. D. Brand, and F. Goglia, “Effect of 3,5-di-iodo-L-thyronine on the mitochondrial energy-transduction apparatus,” Biochemical Journal, vol. 330, part 1, pp. 521–526, 1998.
- A. Lanni, M. Moreno, M. Cioffi, and F. Goglia, “Effect of 3,3′-di-iodothyronine and 3,5-di-iodothyronine on rat liver mitochondria,” Journal of Endocrinology, vol. 136, no. 1, pp. 59–64, 1993.
- A. Del Viscovo, A. Secondo, A. Esposito, F. Goglia, M. Moreno, and L. M. Canzoniero, “Intracellular and plasma membrane-initiated pathways involved in the [Ca2+ elevations induced by iodothyronines (T3 and T2) in pituitary GH3 cells,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 302, no. 11, pp. E1419–E1430, 2012.
- S. G. Ball, J. Sokolov, and W. W. Chin, “3,5-diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro,” Journal of Molecular Endocrinology, vol. 19, no. 2, pp. 137–147, 1997.
- J. C. Strum, R. Shehee, D. Virley et al., “Rosiglitazone induces mitochondrial biogenesis in mouse brain,” Journal of Alzheimer's Disease, vol. 11, no. 1, pp. 45–51, 2007.
- Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006.
- A. A. Eissa Ahmed and N. M. Al-Rasheed, “Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests,” Behavioural Pharmacology, vol. 20, no. 7, pp. 635–642, 2009.
- N. L. Rasgon, H. A. Kenna, K. E. Williams, B. Powers, T. Wroolie, and A. F. Schatzberg, “Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study,” TheScientificWorldJOURNAL, vol. 10, pp. 321–328, 2010.
- D. E. Kemp, F. Ismail-Beigi, S. J. Ganocy et al., “Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity,” Journal of Affective Disorders, vol. 136, no. 3, pp. 1164–1173, 2011.
- B. H. Cline, H. W. Steinbusch, D. Malin, et al., “The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2,” BMC Neuroscience, vol. 13, article 110, 2012.
- T. Strekalova, Y. Couch, N. Kholod et al., “Update in the methodology of the chronic stress paradigm: internal control matters,” Behavioral and Brain Functions, vol. 7, article 9, 2011.
- T. Strekalova and H. M. W. Steinbusch, “Updated methodology of the chronic stress depression model: importance of internal control,” in Proceedings of the International Neuroscince Symposium of the Champalimaud Foundation, Lisbon, Portugal, September 2011.
- J. F. Cryan, C. Mombereau, and A. Vassout, “The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice,” Neuroscience and Biobehavioral Reviews, vol. 29, no. 4-5, pp. 571–625, 2005.
- M. Moreno, A. Lombardi, L. Beneduce et al., “Are the effects of T3 on resting metabolic rate in euthyroid rats entirely caused by T3 itself?” Endocrinology, vol. 143, no. 2, pp. 504–510, 2002.
- Y. Couch, D. C. Anthony, O. Dolgov, et al., “Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia,” Brain, Behavior, and Immunity, vol. 29, pp. 136–146, 2013.
- T. Strekalova, R. Spanagel, D. Bartsch, F. A. Henn, and P. Gass, “Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration,” Neuropsychopharmacology, vol. 29, no. 11, pp. 2007–2017, 2004.
- E. Malatynska, H. W. Steinbusch, O. Redkozubova, et al., “Anhedonic-like traits and lack of affective deficits in 18-month-old C57BL/6 mice: implications for modeling elderly depression,” Experimental Gerontology, vol. 47, no. 8, pp. 552–564, 2012.
- M. W. Pfaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, no. 9, article e45, 2001.
- J. Vignisse, H. W. M. Steinbusch, A. Bolkunov et al., “Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 510–522, 2011.
- T. Strekalova, D. C. Anthony, O. Dolgov, et al., “The differential effects of chronic imipramine or citalopram administration on physiological and behavioral outcomes in naïve mice,” Behavioural Brain Research, vol. 245, pp. 101–106, 2013.
- P. Willner, “Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS,” Neuropsychobiology, vol. 52, no. 2, pp. 90–110, 2005.
- M. Hamilton, “Development of a rating scale for primary depressive illness,” The British Journal of Social and Clinical Psychology, vol. 6, no. 4, pp. 278–296, 1967.
- J. Harro, M. Tonissaar, M. Eller, A. Kask, and L. Oreland, “Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: effects on behavior and monoamine neurochemistry,” Brain Research, vol. 899, no. 1-2, pp. 227–239, 2001.
- T. Strekalova, N. Gorenkova, E. Schunk, O. Dolgov, and D. Bartsch, “Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress,” Behavioural Pharmacology, vol. 17, no. 3, pp. 271–287, 2006.
- Y. Ibarguen-Vargas, A. Surget, P. Vourc'h et al., “Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress,” Behavioural Brain Research, vol. 202, no. 2, pp. 245–251, 2009.
- V. A. Galton, E. T. Wood, E. A. St Germain et al., “Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development,” Endocrinology, vol. 148, no. 7, pp. 3080–3088, 2007.
- M. Castillo, J. A. Hall, M. Correa-Medina et al., “Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality,” Diabetes, vol. 60, no. 4, pp. 1082–1089, 2011.
- E. C. Friesema, S. Ganguly, A. Abdalla, J. E. Manning Fox, A. P. Halestrap, and T. J. Visser, “Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter,” The Journal of Biological Chemistry, vol. 278, no. 41, pp. 40128–40135, 2003.
- L. M. Roberts, K. Woodford, M. Zhou et al., “Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier,” Endocrinology, vol. 149, no. 12, pp. 6251–6261, 2008.
- G. Schreiber, A. R. Aldred, A. Jaworowski, C. Nilsson, M. G. Achen, and M. B. Segal, “Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus,” The American Journal of Physiology, vol. 258, no. 2, part 2, pp. R338–R345, 1990.